Goldman Sachs to Biotech: Don’t Cure Cancer

Cancer is a growth industry. And drug companies are not interested in curing cancer. It is more profitable to turn it into a chronic condition. They can then offer “chronic treatments.” Patients will keep coming back  for expensive treatments. This isn’t idle speculation. In April 2018, Goldman Sachs, a Wall St. bank with almost one trillion … Continue reading Goldman Sachs to Biotech: Don’t Cure Cancer